Agios Pharm

Yahoo Finance • 5 days ago

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: UiPath Inc.(NYSE:PATH) shares gained in extended trading on Tuesday after it was announced tha... Full story

Yahoo Finance • 8 days ago

Here's Why Shares in Agios Pharmaceuticals Popped Today

Key Points The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the y... Full story

Yahoo Finance • 8 days ago

U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) rem... Full story

Yahoo Finance • 24 days ago

Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story

Yahoo Finance • 29 days ago

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight

DelveInsight Business Research LLP The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug developme... Full story

Yahoo Finance • last month

Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) ranks among the most oversold biotech stocks to invest in. On November 20, Leerink Partners upgraded Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from Market Perform to Outperform with a $34 price tar... Full story

Yahoo Finance • last month

Stocks Settle Higher Before Nvidia Earnings

The S&P 500 Index ($SPX) (SPY) on Wednesday closed up by +0.38%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +0.56%.  December E-mini S&P futures (ESZ25) rose +0.39... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Stocks Supported by Strength in Megacap Tech and Chip Stocks

The S&P 500 Index ($SPX) (SPY) today is up by +0.38%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.22%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.74%.  December E-mini S&P futures (ESZ25) are up +0.39%, and December... Full story

Yahoo Finance • last month

Oversold Conditions For Agios Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • last month

Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in pr... Full story

Yahoo Finance • 2 months ago

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story

Yahoo Finance • 2 months ago

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

$12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RIS... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Altria Group (MO [https://seekingalpha.com/symbol/MO]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Enterprise Products Partners L.P. (EPD [https://seekin... Full story

Yahoo Finance • 2 months ago

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that... Full story

Yahoo Finance • 3 months ago

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 4 months ago

Top movers in Thursday's pre-market session

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT BRIA [https://www.chartmill.com/st... Full story

Yahoo Finance • 4 months ago

Commit To Buy Agios Pharmaceuticals At $30, Earn 34.9% Annualized Using Options

Investors eyeing a purchase of Agios Pharmaceuticals Inc (Symbol: AGIO) stock, but tentative about paying the going market price of $38.20/share, might benefit from considering selling puts among the alternative strategies at their disposa... Full story

Yahoo Finance • 4 months ago

CLF Crosses Above Average Analyst Target

In recent trading, shares of Cleveland-Cliffs Inc (Symbol: CLF) have crossed above the average analyst 12-month target price of $15.36, changing hands for $15.58/share. When a stock reaches the target an analyst has set, the analyst logi... Full story